Work

A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.e13599

Authors: Khurum Hayat Khan, Li Yan, Janusz Mezynski, Amita Patnaik, Victor Moreno, Kyriakos P. Papadopoulos, Chris R. Garrett, Michael Ong, Keith A. Shannon, Anne Morosky, Eric H. Rubin, Ernestina Tetteh, Jeffrey Skolnik, Ian C. Smith, Paul D. Smith, Johann Sebastian De Bono, Anthony W. Tolcher

Institutions: Royal Marsden Hospital, South Texas Accelerated Research Therapeutics, Institute of Cancer Research, The University of Texas MD Anderson Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), AstraZeneca (United Kingdom)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2336866290

Cites:

Cited by: 36

Related to: 10